# LITESPARK-003 (NCT03634540)

> A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

No report yet. It can be ordered.

- Drugs tested: belzutifan plus cabozantinib
- Indication: advanced clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03634540
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Conditions: Renal Cell Carcinoma (RCC); Clear Cell Renal Cell Carcinoma (ccRCC); Kidney Cancer; Renal Cancer; Renal Cell Carcinoma; Renal Cell Cancer Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Cancer, Recurrent; Kidney
- Interventions: Belzutifan; Cabozantinib
- Enrollment: 118
- Primary outcome: Overall Response Rate (ORR)

## Indexed commentary on LITESPARK-003 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 8 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=litespark-003-nct03634540

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03634540", "email": "<work email>"}; the inbox owner confirms by the emailed link.